No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide Sensitive: A1 - Approval pomalidomide Sensitive : A1	pomalidomide Sensitive: A1 - Approval pomalidomide Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval lenalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1	lenalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval lenalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + elotuzumab Sensitive: A1 - Approval lenalidomide + elotuzumab Sensitive : A1	lenalidomide + elotuzumab Sensitive: A1 - Approval lenalidomide + elotuzumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + daratumumab Sensitive: A1 - Approval lenalidomide + daratumumab Sensitive : A1	lenalidomide + daratumumab Sensitive: A1 - Approval lenalidomide + daratumumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + ixazomib Sensitive: A1 - Approval lenalidomide + ixazomib Sensitive : A1	lenalidomide + ixazomib Sensitive: A1 - Approval lenalidomide + ixazomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lenalidomide + tafasitamab-cxix Sensitive: A1 - Approval lenalidomide + tafasitamab-cxix Sensitive : A1	lenalidomide + tafasitamab-cxix Sensitive: A1 - Approval lenalidomide + tafasitamab-cxix Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + isatuximab-irfc Sensitive: A1 - Approval pomalidomide + isatuximab-irfc Sensitive : A1	pomalidomide + isatuximab-irfc Sensitive: A1 - Approval pomalidomide + isatuximab-irfc Sensitive : A1

IL-6 inhibitor

IL-6 inhibitor

Associations(145)

Associations
(145)